Table 2.
Pharmacokinetic variables of plasma folate concentration in women with the TT (n= 16) or CC (n= 8) genotype of the 677C→T mutation of MTHFR
| FA | [6S]-5-MTHF | P | ||
|---|---|---|---|---|
| AUC (nM) adjusted for time | TT | 10.8 ± 2.9 (9.3–12.4) | 21.4 ± 4.6 (19.0–23.9) | <0.0001 |
| CC | 11.9 ± 2.9 (9.5–14.3) | 19.2 ± 4.5 (15.4–22.9) | 0.0012 | |
| Cmax (nM) | TT | 43.4 ± 12.4 (36.8–50.0) | 71.1 ± 13.5 (63.9–78.3) | <0.0001 |
| CC | 48.0 ± 13.5 (36.7–59.3) | 66.5 ± 12.7 (55.9–77.1) | 0.0006 | |
| tmax (min) | TT | 119.4 ± 69.2§ (82.5–156.3) | 33.3 ± 10.9 (27.5–39.1) | 0.0002 |
| CC | 79.0 ± 27.9 (55.6–102.3) | 36.9 ± 14.2 (25.0–48.7) | 0.0134 |
The data are presented as the arithmetic mean ± SD, with the 95% CI in parentheses. Student.s t-test was used to assess differences between the variables.
§
Significantly different from tmax after FA application in the CC genotype, P= 0.0217.
[6S]-5-MTHF, [6S]-5-methyltetrahydrofolate; AUC, concentration–time profiles of total plasma folate concentration; CC, CC genotype of the 677C→T mutation of the 5,10-methylenetetrahydrofolate reductase; FA, folic acid; TT, TT genotype of the 677C→T mutation of the 5,10-methylenetetrahydrofolate reductase.